Recce Pharmaceuticals Ltd. (RCE) Price & Analysis

Compare

21 Followers

RCE Stock Chart & Stats

AU$0.41

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.41

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.28 - AU$0.73

Previous CloseN/A

Volume21.12K

Average Volume (3M)154.69K

Market Cap

AU$170.62M

Enterprise ValueAU$170.94M

Total Cash (Recent Filing)AU$10.45M

Total Debt (Recent Filing)AU$10.77M

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Mar 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding289,183,400

10 Day Avg. Volume112,630

30 Day Avg. Volume154,688

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)-22.52

Price to Sales (P/S)9.15

P/FCF Ratio-3.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Anti-infective PlatformRecce’s synthetic polymer anti-infective platform targets drug-resistant bacterial infections, a persistent structural healthcare need. A platform approach can generate multiple candidates from shared chemistry, supporting durable R&D optionality and potential long-term franchise value as programs advance through clinical validation.

Free Cash Flow ExpansionA 51.97% rise in free cash flow is a durable improvement in internal funding capacity, helping extend the development runway and partially reduce near-term financing pressure. Over months, stronger FCF supports continued trials and R&D without immediate reliance on dilutive capital events.

Focused Clinical PipelineRecce is a clinical-stage biotech with a clear lead program (RECCE 327) and pipeline focus. Concentrated clinical development efforts provide measurable milestones and de-risking steps; progress in trials and regulatory filings materially alters long-term value and strategy over quarters to a year.

Bears Say

Declining Revenue And Steep LossesSignificant revenue decline combined with extremely negative EBIT and net margins indicates persistent cash burn and weak commercial traction. Over the medium term, sustained losses deepen funding needs and increase dependence on external financing to support clinical programs and operations.

Negative Equity / High LeverageNegative equity and a debt-to-equity of -3.53 materially weaken financial flexibility, constraining borrowing capacity and strategic options. This structural balance-sheet weakness raises refinancing and covenant risk and can force financing on unfavorable terms, affecting long-term program funding.

Operating Cash Flow ShortfallNegative operating cash flow relative to net losses means core operations do not cover spending. Reliance on financing to bridge the gap is likely, increasing dilution or debt risk. Over months, this undermines sustainability unless operating cash conversion improves or external funding is secured.

Recce Pharmaceuticals Ltd. News

Recce Pharmaceuticals Deepens U.S. Army Ties With New Burn Wound Gel Study

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an update. Recce Pharmaceuticals has signed a new Cooperative Research...

15d ago

Recce Advances Phase 3 Diabetic Foot Trial and Strengthens Anti-Infective Pipeline

An announcement from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) is now available. Recce Pharmaceuticals reported significant operational progress...

17d ago

Recce Pharmaceuticals Secures $5.3m R&D Rebate to Bolster Anti-Infective Pipeline

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has issued an announcement. Recce Pharmaceuticals has received an AUD $5.34 million...

1M ago

Recce Pharmaceuticals Secures A$85 Million R&D Tax Incentive for Global Anti-Infective Programs

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has shared an update. Recce Pharmaceuticals has been awarded an Advanced Overseas...

2M ago

Recce Pharmaceuticals Secures Hong Kong Patent for Anti-Infectives

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has provided an update. Recce Pharmaceuticals Ltd. announced the granting of a...

3M ago

Recce Pharmaceuticals Reports Promising Preclinical Results for Inhaled RECCE® 327

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has issued an announcement. Recce Pharmaceuticals Ltd. announced positive preclinical results for...

3M ago

Recce Pharmaceuticals Mourns the Loss of Founder Dr. Graham JH Melrose

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) has shared an announcement. Recce Pharmaceuticals Ltd. announced the passing of its...

3M ago

Recce Pharmaceuticals Ltd 2025 AGM Results Announced

The latest update is out from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ). Recce Pharmaceuticals Ltd held its 2025...

3M ago

Recce Pharmaceuticals Outlines Future Strategies at 2025 AGM

Recce Pharmaceuticals Ltd. ( ($AU:RCE) ) just unveiled an update. Recce Pharmaceuticals Ltd presented at their Annual General...

3M ago

Recce Pharmaceuticals Advances Phase 3 Trial for Diabetic Foot Infections in Indonesia

The latest announcement is out from Recce Pharmaceuticals Ltd. ( ($AU:RCE) ). Recce Pharmaceuticals Ltd has commenced patient...

4M ago

RCE FAQ

What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?

Recce Pharmaceuticals Ltd. lowest share price was AU$0.28 and its highest was AU$0.73 in the past 12 months.

What is Recce Pharmaceuticals Ltd.’s market cap?

Recce Pharmaceuticals Ltd.’s market cap is AU$170.62M.

When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?

Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Mar 02, 2026 which is in 14 days.

How were Recce Pharmaceuticals Ltd.’s earnings last quarter?

Recce Pharmaceuticals Ltd. released its earnings results on Aug 29, 2025. The company reported -AU$0.057 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.057.

Is Recce Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Recce Pharmaceuticals Ltd. pay dividends?

Recce Pharmaceuticals Ltd. does not currently pay dividends.

What is Recce Pharmaceuticals Ltd.’s EPS estimate?

Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Recce Pharmaceuticals Ltd. have?

Recce Pharmaceuticals Ltd. has 289,183,400 shares outstanding.

What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?

Recce Pharmaceuticals Ltd. reported an EPS of -AU$0.057 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:RCE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Recce Pharmaceuticals Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

94.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Recce Pharmaceuticals Ltd.

Recce Pharmaceuticals Ltd. (RCE) is a biotechnology company focused on the development and commercialization of innovative anti-infective therapies. The company specializes in creating synthetic polymers to combat serious infections, particularly those caused by antibiotic-resistant bacteria. Recce's lead product candidate, RECCE 327, is designed to treat a range of infections, including sepsis, and is positioned to address the growing global health challenge of antibiotic resistance.